Article Text

Download PDFPDF
DOACs not recommended for people with antiphospholipid syndrome

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Review of: Medicines and Healthcare products Regulatory Agency. Direct-acting anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome. Drug Safety Update 2019;12(11):1.

Key learning points

  • Direct-acting oral anticoagulants are not recommended for patients with antiphospholipid syndrome.

  • Prescribers should review patients with antiphospholipid syndrome who are taking a direct-acting oral anticoagulant and consider switching to a vitamin K antagonist.

  • Patients at particularly high risk are those who are positive for all three antiphospholipid tests.

An EU-wide review has concluded that in patients with antiphospholipid syndrome use of a direct-acting oral anticoagulant could be associated with an increased rate of recurrent thrombotic events compared with therapy with a vitamin K antagonist.1

Safety alert details

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised that direct-acting oral anticoagulants (DOACs) should not …

View Full Text


  • Contributors DTB team.

  • Provenance and peer review Commissioned; internally peer reviewed.